Numerate, the world’s leading computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery has acquired DeepCrystal’s small molecule design platform.
San Bruno, CA – Numerate, the world’s leading computational drug design company applying artificial intelligence (AI) at cloud scale to transform small molecule drug discovery has acquired DeepCrystal’s small molecule design platform. The platform is used to build models of compound activity and ADME based on advances in graph-valued deep-learning technology. These methods will augment Numerate’s existing AI platform by compressing timelines to facilitate the discovery of next generation therapeutics.
As part of the acquisition, Patrick Hop, the Founder of DeepCrystal, will join Numerate as Principal Engineer of Deep Learning. At DeepCrystal, Mr. Hop was responsible for the development of its core technology and platform, as well as leading the company into strategic partnerships with top pharmaceutical companies to advance in-silico modeling. He holds a B.A in Applied Mathematics from UC Berkeley, and serves as a mentor to River Accelerator.
“We are excited to have Patrick join our team and bring his extensive experience in applying deep learning to drug discovery,” said Brandon Allgood, Ph.D., Chief Technology Officer at Numerate. “His research and insights combined with our expertise of applying AI to drug discovery will be synergistic.”
“I’m excited to begin working with the world-class engineering and scientific teams at Numerate,” said Mr. Hop. “Among the groups working in this space, I believe Numerate is the one striking the right balance of AI technology, and classical drug-discovery experience which, combined with the deep-learning technology from DeepCrystal, will help identify new therapies for patients faster and with less capital investment than ever before.”
